The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
Implements Bayesian phase I repeated measurement design that accounts for multidimensional toxicity endpoints and longitudinal efficacy measure from multiple treatment cycles. The package provides flags to fit a variety of model-based phase I design, including 1 stage models with or without individualized dose modification, 3-stage models with or without individualized dose modification, etc. Functions are provided to recommend dosage selection based on the data collected in the available patient cohorts and to simulate trial characteristics given design parameters. Yin, Jun, et al. (2017) <doi:10.1002/sim.7134>.
| Version: | 1.0.2 |
| Depends: | R (≥ 3.0.0), coda (≥ 0.13), ggplot2, stats |
| Imports: | rjags, arrayhelpers, MASS, reshape2, plyr, dplyr, RColorBrewer, gridExtra, kableExtra, knitr |
| Published: | 2020-03-09 |
| DOI: | 10.32614/CRAN.package.phase1PRMD |
| Author: | Lu Zhang, Jun Yin |
| Maintainer: | Lu Zhang <luzhangstat at gmail.com> |
| License: | GPL-2 | GPL-3 [expanded from: GPL (≥ 2)] |
| NeedsCompilation: | no |
| SystemRequirements: | JAGS (http://mcmc-jags.sourceforge.net) |
| Materials: | README NEWS |
| CRAN checks: | phase1PRMD results |
| Reference manual: | phase1PRMD.pdf |
| Package source: | phase1PRMD_1.0.2.tar.gz |
| Windows binaries: | r-devel: phase1PRMD_1.0.2.zip, r-release: phase1PRMD_1.0.2.zip, r-oldrel: phase1PRMD_1.0.2.zip |
| macOS binaries: | r-release (arm64): phase1PRMD_1.0.2.tgz, r-oldrel (arm64): phase1PRMD_1.0.2.tgz, r-release (x86_64): phase1PRMD_1.0.2.tgz, r-oldrel (x86_64): phase1PRMD_1.0.2.tgz |
| Old sources: | phase1PRMD archive |
Please use the canonical form https://CRAN.R-project.org/package=phase1PRMD to link to this page.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.